1.	Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesilate in Patients With Inoperable or Recurrent Breast Cancer Phase: Phase IV Type: Treatment Status: Closed Age: Not specified Sponsor: Pharmaceutical / Industry Protocol IDs: HAL01S, NCT01463891
2.	E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7389-G000-301, NCT00337103
3.	E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7389-G000-305, NCT00388726
4.	Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7389-701, 2009-016047-19, NCT01126736
5.	Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7389-702, 2009-015915-42, NCT01126749
6.	A Study of E7389 in Advanced/Metastatic Breast Cancer Patients Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7389-A001-201, NCT00097721
7.	Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7389-A001-202, NCT00100932
8.	A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7389-G000-211, NCT00246090
9.	Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7389-G000-204, NCT00278993
10.	S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000481530, U10CA032102, S0618, SWOG-S0618, NCT00337129
11.	Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00169, 06-027, CDR0000481534, N01CM17105, MSKCC-06027, 7431, NCI-7431, NCT00334893
12.	E7389 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000482413, ECOG-E5805, E5805, NCT00337077
13.	Phase II Study of E7389 as Second-Line Therapy in Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: PMH-PHL-049, 7448, NCI-7448, NCT00383760
14.	E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000514516, P30CA033572, CCC-PHII-74, 7437, NCT00400829
15.	Phase II Study of E7389 in Patients With Advanced and/or Metastatic Soft Tissue Sarcoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: EORTC-62052, EISAI-E7389-E044-207, EUDRACT-2005-004272-20, NCT00413192
16.	Phase II Clinical Study of E7389 for Advanced or Relapsed Breast Cancer Phase: Phase II Type: Treatment Status: Completed Age: 20 to 75 Sponsor: Pharmaceutical / Industry Protocol IDs: E7389-J081-221, NCT00633100
17.	A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer Phase: Phase II Type: Supportive care, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7389-G000-209, NCT00879086
18.	Continuation Study of E7389 for Advanced or Relapsed Breast Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 20 to 74 Sponsor: Pharmaceutical / Industry Protocol IDs: E7389-J081-224, NCT00965523
19.	Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7389-G000-205, NCT01104155
20.	A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7389-A001-206, NCT01268150
21.	Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7389-A001-212, NCT01439282
22.	E7389 in Treating Patients With Advanced Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000257235, P30CA033572, CCC-PHI-39, CHNMC-PHI-39, NCI-5730, 5730, NCT00047034
23.	Study of E7389 Administered Once Every 3 Weeks In Patients With Advanced Solid Tumors Phase: Phase I Type: Treatment Status: Completed Age: over 18 Sponsor: Pharmaceutical / Industry Protocol IDs: E7389-A001-102, NCT00069277
24.	A Dose-Finding Study of E7389 in Combination With Carboplatin in Patients With Solid Tumors Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7389-A001-104, NCT00268905
25.	Phase I Clinical Study of E7389 Phase: Phase I Type: Treatment Status: Completed Age: 20 to 74 Sponsor: Pharmaceutical / Industry Protocol IDs: E7389-J081-105, NCT00326950